TauRx is a group of life science companies focused on the development of novel treatments and diagnostics for Alzheimer’s disease and other neurodegenerative diseases. A leader in Alzheimer’s disease research, TauRx is pioneering a new pathway to treating the disease.
The company was established in 2002.
TauRx Pharmaceuticals Ltd.’s commercial headquarters is based in Singapore, and its research base is in Aberdeen, Scotland.
TauRx Pharmaceuticals Ltd. is the group holding company and financing vehicle. TauRx Therapeutics Ltd. is responsible for the commercialisation of LMTX® as a therapeutic product. WisTa Laboratories Ltd. is the discovery and early-stage development engine for the group. It is currently planned that PoreDeen Pte. Ltd. will undertake the development of novel products for the treatment of Parkinson’s disease. Genting TauRx Diagnostic Centre Sdn. Bhd. is developing innovative tools and systems for the early detection, diagnosis and treatment of AD, FTD and other related disorders and plans to establish integrated detection, diagnosis and treatment centres for such disorders in SE Asia.
Professor Wischik, co-founder of TauRx, holds the Chair of Old-Age Psychiatry at Aberdeen University. When he joined the university in 1996, he and his team of bioscientists pioneered the early research into, and development of, tau aggregation inhibitors to slow and halt the progression of Alzheimer’s disease (AD). Once the foundational research showed promise, TauRx, the Company, was founded in order to focus on the commercial aspects of pursuing hopeful drug candidates, including attracting investment for this long process. TauRx remains closely linked to the University of Aberdeen’s School of Chemistry, its Institute of Medical Sciences, its Department of Mathematics and Complex Systems, and its Department of Neuroradiology.
TauRx management and shareholders continue to explore a variety of sources of additional financing to support the on-going development of their lead compound LMTX® for the treatment of Alzheimer’s disease. A listing of the company’s shares will depend upon market conditions and will be the subject of a separate announcement at the appropriate time.
Three Phase 3 clinical trials have recently completed. Information on this programme is available on the Clinical Trials page of this website. TauRx is currently preparing for further Phase 3 trials to test the potential of their lead compound, LMTX®, as monotherapy in mild and moderate Alzheimer’s disease.
Our Phase 3 trials originally set out to test our lead compound LMTX® in patients with mild to moderate Alzheimer’s disease. Many patients diagnosed with Alzheimer’s may be receiving other medications approved for the management of the symptoms of their disease, and so LMTX® was given to many patients on the trials as ‘add-on’ therapy. Our Phase 3 trial data show that LMTX® may have greater potential when taken as a monotherapy (i.e. without currently approved symptomatic treatments for Alzheimer’s disease) as a treatment to reduce the rate of progression of Alzheimer’s disease. Additional information on the trial results is available on the Clinical Trials pages of this website.
TauRx will need to undertake one or more additional clinical studies of LMTX® in order to demonstrate its effectiveness as a potential monotherapy for the treatment of Alzheimer’s disease. Once this is completed, it will be easier to forecast a potential launch date.